Overview

Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations

Status:
NOT_YET_RECRUITING

Trial end date:
2035-12-01

Target enrollment:

Participant gender:

Summary

This study explores how adjuvant therapy affects survival in completely resected high-risk stage IA-IB NSCLC patients with different driver gene mutations.

Phase:

PHASE3

Details

Lead Sponsor:

The First Affiliated Hospital of Guangzhou Medical University

Treatments:

ensartinib
icotinib
rezivertinib